Meiji Seika Pharma to Expand CMO Business with India Manufacturing Site

On November 8, Japan’s Meiji Seika Pharma invested $20.1 million to build a manufacturing site in India. According to the company, the move will boost the production capacity of its contract manufacturing organization (CMO) business, and also contribute to the Meiji Group 2026 Vision.

To Start Operation in March 2023

The facility covers 8,000 square meters and has an annual output of 750 million tablets, 75 million packages, and 4 million bottles. It will be established in a factory currently operated by Adcock Ingram, a joint venture between South Africa’s Adcock Ingram Holdings and a wholly-owned subsidiary of Meiji Seika Pharma, Medreich. In addition, the products manufactured in Adcock Ingram will be distributed to South African, European, and Oceanian markets.

The plant is expected to begin operations in March 2023, the company said.

Part of the Meiji Group 2026 Vision

As part of the stage 3 plan in the Meiji Group 2026 Vision, the 2023 Medium-Term Business Plan involved 2 goals, which are integrating business operations of Meiji Seika Pharma and KM Biologics and expanding CMO/CDMO business. The former focuses on strengthening the vaccine business, which includes a Covid-19 vaccine, a DTaP-IPV/Hib vaccine, and a dengue vaccine while the latter aims to enlarge the production and  R&D capacity of CMO/CDMO.

In the 2026 Vision, Meiji expects its pharmaceutical segment to bring operational income at a CAGR of 9%, and to reach over 30% in overseas sales ratio in FYE 3/2027. The firm said it will increase the sales of infectious disease products, generic drugs, and biopharmaceuticals in Japan and overseas with the goal of becoming the leading company in Asia in the infectious disease domain.

Author

Tyler Chen

"Never go to a doctor whose office plants have died."- Erma Bombeck